The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Completed
Pfizer
Phase 3
2010-10-01
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity
for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet
been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and
safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin
sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.
Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
Completed
DongGuk University
2015-05-01
This study purposed to examine the adequate range of therapeutic concentration for Korean
people by observing curative effects, side effects, blood concentration, etc. in treating
CRAB-infected patients with colistin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
